<DOC>
	<DOCNO>NCT00005033</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , trastuzumab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness trastuzumab treat patient recurrent osteosarcoma .</brief_summary>
	<brief_title>Trastuzumab Treating Patients With Recurrent Osteosarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate , freedom progression , survival patient recurrent osteosarcoma treat trastuzumab ( Herceptin ) . - Evaluate toxicity drug young patient history osteosarcoma prior therapy doxorubicin . OUTLINE : This multicenter study . Patients receive trastuzumab ( Herceptin ) IV 30-90 minute weekly . Treatment continue 52 week absence disease progression unacceptable toxicity . After approximately 12 week treatment , patient evaluate response undergo surgical resection clinically appropriate . Patients follow 1 year survival . PROJECTED ACCRUAL : Approximately 20-40 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent osteosarcoma initial systemic therapy doxorubicin Measurable disease Immunohistochemical evidence 2+ overexpression HER2 PATIENT CHARACTERISTICS : Age : Any age Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : ALT AST less 3 time upper limit normal ( ULN ) Bilirubin le 1.5 time ULN Renal : Creatinine le 1.5 time ULN OR Creatinine clearance great 60 mL/min Cardiovascular : Fractional shortening least 29 % echocardiogram OR Ejection fraction least 50 % MUGA No prior cardiac dysfunction , even presently control Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No prior anthracycline 450 mg/m^2 Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent cancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>recurrent osteosarcoma</keyword>
</DOC>